Compounds > ubp296
Page last updated: 2024-11-12

ubp296

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

UBP296: potent and selective kainate receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11674376
CHEMBL ID372631
CHEBI ID91719
SCHEMBL ID2265718
MeSH IDM0472841

Synonyms (23)

Synonym
HMS3268J09
HMS3268J11
CHEMBL372631 ,
bdbm50178148
(rs)-1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione
ubp 296
BRD-A45499626-001-01-0
SCHEMBL2265718
745055-86-1
AKOS024456931
SR-01000597532-1
sr-01000597532
CHEBI:91719
2-[[3-(2-amino-2-carboxyethyl)-2,6-dioxo-1-pyrimidinyl]methyl]benzoic acid
Q27163534
HMS3677E09
HMS3413E09
BRD-A45499626-001-02-8
2-((3-(2-amino-2-carboxyethyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6h)-yl)methyl)benzoic acid
2-[[3-(2-amino-2-carboxyethyl)-2,6-dioxopyrimidin-1-yl]methyl]benzoic acid
ubp296
CS-0028946
HY-107605

Research Excerpts

Overview

UBP296 was found to be a potent and selective antagonist of native GLUK5-containing kainate receptors in the spinal cord, with activity residing in the S enantiomer (UBP302)

ExcerptReferenceRelevance
"UBP296 was found to be a potent and selective antagonist of native GLUK5-containing kainate receptors in the spinal cord, with activity residing in the S enantiomer (UBP302)."( Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist.
Alt, AJ; Bleakman, D; Bortolotto, ZA; Buelens, FP; Clarke, VR; Collingridge, GL; Dolman, NP; Jane, DE; Kelland, EE; More, JC; Nistico, R; Ogden, AM; Pilato, F; Troop, HM, 2004)		1.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alpha-amino acidAn amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)97.60000.00011.617910.0000AID257196
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)97.60000.00011.700010.0000AID257196
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)97.60000.00011.700010.0000AID257196
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)97.60000.00011.700010.0000AID257196
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)Ki1,000.00000.00370.80254.1000AID257202
Glutamate receptor ionotropic, kainate 3Homo sapiens (human)IC50 (µMol)880.00000.07702.03854.0000AID257203
Glutamate receptor ionotropic, kainate 3Homo sapiens (human)Ki374.00000.01000.39950.7890AID257203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Kd1.09000.01801.27203.9400AID257198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, kainate 1Homo sapiens (human)Kb0.60000.00800.40301.0000AID257204
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
nervous system developmentGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
central nervous system developmentGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
glutamate-gated receptor activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
kainate selective glutamate receptor activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
kainate selective glutamate receptor activityGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
intracellular membrane-bounded organelleGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
kainate selective glutamate receptor complexGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
axonGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
dendriteGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
dendrite cytoplasmGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
perikaryonGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
kainate selective glutamate receptor complexGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, kainate 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID257200Displacement of [3H](S)-5-fluorowillardiine from AMPA receptor in rat brain membrane2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257210Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUA2 receptor expressed in HEK293 cells up to 300 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257208Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUK6/GLUK2 receptor clone expressed in HEK293 cells up to 300 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257203Displacement of [3H]kainate from human GLUK7 receptor expressed in HEK293 cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257202Displacement of [3H]kainate from rat GLUK6 receptor expressed in HEK293 cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257196Antagonist activity on AMPA receptor expressed on rat motoneurons by its ability to reduce the fast component dorsal root evoked ventral root potential (fDR-VRP)2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257201Displacement of [3H]SYM2081 from kainate receptor in rat brain membrane2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257209Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUA1 receptor expressed in HEK293 cells up to 300 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257204Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUK5 receptor expressed in HEK293 cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257198Antagonism on GLUK5 containing kainate induced depolarization of isolated neonatal rat dorsal root C-fibers2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257205Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUK5/GLUK2 receptor clone expressed in HEK293 cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257206Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUK5/GLUK6 receptor clone expressed in HEK293 cells2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257207Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUK6 receptor expressed in HEK293 cells up to 300 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257211Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUA3 receptor expressed in HEK293 cells up to 300 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
AID257212Inhibitory effect on glutamate-induced calcium influx at homomeric human GLUA4 receptor expressed in HEK293 cells up to 300 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.		2.0210non-proteinogenic alpha-amino acid
gyki 52466
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source		2.0510benzodiazepine
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.9640alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
sodium cyanide
Sodium Cyanide: A highly poisonous compound that is an inhibitor of many metabolic processes and is used as a test reagent for the function of chemoreceptors. It is also used in many industrial processes.. sodium cyanide : A cyanide salt containing equal numbers of sodium cations and cyanide anions.		2.0510cyanide salt;
one-carbon compound;
sodium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor
kainic acid
Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.		2.4220dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
methoxyhydroxyphenylglycol
Methoxyhydroxyphenylglycol: Synthesized from endogenous epinephrine and norepinephrine in vivo. It is found in brain, blood, CSF, and urine, where its concentrations are used to measure catecholamine turnover.		2.0210methoxybenzenes;
phenols
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		2.0210amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.4420glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
3,4-dihydroxyphenylglycol
3,4-dihydroxyphenylglycol: noradrenaline metabolite in mouse brain; RN given refers to cpd without isomeric designation. 3,4-dihydroxyphenylethyleneglycol : A tetrol composed of ethyleneglycol having a 3,4-dihydroxyphenyl group at the 1-position.		2.0210catechols;
tetrol		metabolite;
mouse metabolite
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
[no description available]		2.0210
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist		2.0210naphthalenes;
sulfonic acid derivative
6-cyano-7-nitroquinoxaline-2,3-dione
6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.		2.0710quinoxaline derivative
dizocilpine maleate
Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.		2.0510maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
ubp 302
[no description available]		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Drug Withdrawal Symptoms
[description not available]		02.0510
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		02.0510
Anoxemia
[description not available]		02.0510
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.0510